Pangaea Oncology S.A. Cash Flow-to-Debt Ratio
Pangaea Oncology S.A. cash flow-to-debt ratio. Pangaea Oncology S.A. (PANG) has a Cash Flow-to-Debt Ratio of -0.12x as of December 2025, meaning its operating cash flow of €-1.25 Million could theoretically repay 0% of its total liabilities (€10.05 Million) in one year. Check Pangaea Oncology S.A. (PANG) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Pangaea Oncology S.A. (2013–2025)
Cash flow-to-debt ratio of Pangaea Oncology S.A. from 2013 to 2025. Historical debt coverage capacity for Pangaea Oncology S.A. across 13 annual periods. Also explore PANG shareholders equity momentum to track the company's year-over-year net asset growth rate.
Pangaea Oncology S.A. Cash Flow-to-Debt Ratio by Year (2013–2025)
Pangaea Oncology S.A. cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for Pangaea Oncology S.A.. For the full cash flow conversion analysis, see cash flow conversion of Pangaea Oncology S.A..
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.25x | €-2.52 Million | €10.05 Million | ▲ +47.4% |
| 2024 | -0.48x | €-4.57 Million | €9.57 Million | ▼ -99.5% |
| 2023 | -0.24x | €-2.40 Million | €10.03 Million | ▲ +65.5% |
| 2022 | -0.69x | €-3.68 Million | €5.30 Million | ▼ -87.6% |
| 2021 | -0.37x | €-2.50 Million | €6.76 Million | ▼ -66.1% |
| 2020 | -0.22x | €-1.92 Million | €8.61 Million | ▲ +20.5% |
| 2019 | -0.28x | €-2.40 Million | €8.56 Million | ▼ -51.7% |
| 2018 | -0.18x | €-2.17 Million | €11.74 Million | ▲ +60.4% |
| 2017 | -0.47x | €-6.48 Million | €13.91 Million | ▼ -211.4% |
| 2016 | -0.15x | €-1.78 Million | €11.89 Million | ▲ +35.5% |
| 2015 | -0.23x | €-2.31 Million | €9.95 Million | ▲ +16.2% |
| 2014 | -0.28x | €-1.89 Million | €6.83 Million | ▼ -97.8% |
| 2013 | -0.14x | €-659.69K | €4.71 Million | — |